Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Therapeutics Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACAA2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Target Enzyme | ACAA2 Recombinant Protein (Full-Length, >95% purity). Sequence Verified. Endotoxin <1 EU/µg. Ideal for biochemical HTS and enzymatic kinetics. | View ACAA2 Products |
| Gene Delivery | ACAA2 Promise-ORF / Lentivirus. Full-length ORF with intact mitochondrial targeting sequence. For stable cell line generation. | View ACAA2 Products |
| Benchmark Ab | Anti-ACAA2 Antibody (Polyclonal/Monoclonal). Recombinant positive control for Western, IHC, IP. | View ACAA2 Products |
| Validator | ACAA2 siRNA Set (3 unique sequences). Sequence-verified for robust knockdown validation and specificity controls. | View ACAA2 Products |
| Paralog Selectivity | ACAA1 (Peroxisomal Thiolase). Purified ortholog (>95% purity). Essential for counter-screening in specificity assays. | View ACAA1 Products |
| Related Target A | CPT1A. Upstream rate-limiting enzyme in mitochondrial fatty acid oxidation. | View CPT1A Products |
| Pathway Partner | HADHA (Mitochondrial Trifunctional Protein α). Upstream β-oxidation enzyme. For pathway studies and co-inhibition. | View HADHA Products |
| Regulatory Node | CPT2 (Carnitine O-Palmitoyltransferase 2). Rate-limiting mitochondrial import. Combination target for metabolic flux analysis. | View CPT2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial vs Peroxisomal Selectivity (ACAA2 vs ACAA1) | Purified Human ACAA2 and ACAA1 Orthologs (>95% purity). Sequence-verified distinct epitopes for specificity screening. Native-like folding with theoretical MW confirmed by SDS-PAGE and Mass Spec. |
| Enzymatic Assay Reproducibility (Thiolase Kinetics) | High-purity active protein (>95%). Endotoxin <1 EU/µg. Catalytic Cys residues preserved. Standard 303 nm enolate absorbance assay. |
| Cellular β-Oxidation Inhibition Verification | ACAA2 Lentivirus particles for stable overexpression/knockdown. Compatible with fatty acid oxidation flux assays (e.g., Seahorse). |
| Target Knockdown & Binding Site Mapping | Validated siRNA sets minimize off-target effects. Full-length native protein with intact mitochondrial leader sequence for competitive binding studies. |
Live ACAA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Metabolic Disease Research
- ➤ β-Oxidation Mechanism Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
Oncology Frontier
ACAA2 (Acetyl-Coenzyme A Acyltransferase 2) acts at the terminal step of mitochondrial fatty acid β-oxidation. It has emerged as a critical vulnerability in metabolically reprogrammed tumors, such as hepatocellular carcinoma, aggressive prostate cancer, and drug-resistant breast cancers. The race for ACAA2 therapeutics is accelerating in the preclinical space, with major players shifting focus from systemic metabolic regulators to targeted small molecule inhibitors within oncology. As early-generation metabolism disruptors advance toward the clinic, the next wave of R&D is targeting the synergistic blockade of lipid metabolism and immune evasion mechanisms.
Metabolic Disease Perspective
ACAA2 is also a strategic node in fatty acid β-oxidation for metabolic syndrome, NASH, and type 2 diabetes. Inhibition promotes metabolic flexibility by forcing glucose utilization over fatty acid oxidation. The focus is shifting from broad CPT1 inhibitors to isoform-specific β-oxidation targets. Combination approaches with GLP-1 agonists and selective mitochondrial modulators aim to minimize cardiac side effects.
Future Directions
- Immuno-metabolic combinations: ACAA2 inhibitors combined with PD-1/L1 antibodies to remodel tumor microenvironment.
- Overcoming drug resistance: FAO upregulation is a key mechanism in chemoresistance; ACAA2 targeting offers a second-line combination strategy.
- Tissue-specific delivery: Liver-targeted nanoparticles or prodrugs for selective β-oxidation modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Metabolic Biotechs, Preclinical Biotech Consortia | Solid Tumors (HCC, Prostate), NASH, T2D, Obesity | Enzyme Activity Assay (need high-purity ACAA2 with intact catalytic Cys residues); Selectivity Assay (ACAA2 vs ACAA1 homolog) |
| Allosteric Modulators | Early Discovery Programs | Metabolic Syndrome | Conformational Binding Studies (need full-length protein with mitochondrial targeting sequence) |
| RNAi / ASO | Academic Spin-offs, Rare Disease Biotechs | Metabolic Syndromes, Cardiac Hypertrophy | Knockdown Validation (need validated siRNA and overexpression lentivirus) |
| Targeted Protein Degraders (PROTACs) | Early Discovery R&D, Targeted Degradation Startups | Drug-Resistant Cancers, Hepatic Steatosis | Ternary Complex Assays (need structurally precise, epitope-intact protein); specific antibodies for pulldown/DC₅₀ determination |